Structure of 3-CYCLOPENTYLACRYLONITRILE CAS 591769-05-0

Iden­ti­fi­ca­tion

CAS Number

591769-05-0

Name

3-CYCLOPEN­TY­LACRY­LONI­TRILE

Syn­onyms

(2E)-3-Cyclopentyl-2-prope­nen­i­trile
(2E)-3-Cyclopenty­lacry­loni­tril [Ger­man] [ACD/IUPAC Name]
(2E)-3-Cyclopenty­lacry­loni­trile [ACD/IUPAC Name]
(2E)-3-Cyclopenty­lacry­loni­trile [French] [ACD/IUPAC Name]
(2E)-3-Cyclopentyl­prop-2-enen­i­trile
1236033-37-6 [RN]
2-Prope­­nen­i­trile, 3-cyclopentyl-, (2E)- [ACD/​Index Name]
3-cyclopentyl­prop-2-enen­i­trile
591769-05-0 [RN]
MFCD11857755 [MDL num­ber]
(E)-3-cyclopentylacrylonitrile
(E)-3-cyclopentylprop-2-enenitrile
[591769-05-0] [RN]
2-Prope­­nen­i­trile, 3-cyclopentyl- [ACD/​Index Name]
30459-17-7 [RN]
3-Cyclopentyl-acry­loni­trile
95%
CA-5126
DS-8986

SMILES

C1CCC(C1)/C=C/C#N

Std­InChI

InChI=1S/C8H11N/c9-7-3-6-8-4-1-2-5-8/h3,6,8H,1-2,4-5H2/b6-3+

Std­InChIKey

VMELXYJYSXXORF-ZZXK­WV­IF­SA-N

Mol­e­c­u­lar Formula

C8H11N

Mol­e­c­u­lar Weight

121.180

MDL Number

MFCD11857755

Prop­er­ties

Appear­ance

Col­or­less to pale yel­low trans­par­ent liquid

Safe­ty Data

Sym­bol

Sig­nal Word

Warn­ing

WGK Germany

3

MSDS Download

Spec­i­fi­ca­tions and Oth­er Infor­ma­tion of Our 3-CYCLOPEN­TY­LACRY­LONI­TRILE CAS 591769-05-0

Puri­ty

98% min

Shelf Life

2 years

Stor­age

Known Appli­ca­tion

3-CYCLOPEN­TY­LACRY­LONI­TRILE CAS 591769-05-0, as an inter­me­di­ate for Rux­oli­tinib, plays a cru­cial role in the syn­the­sis of Rux­oli­tinib. Rux­oli­tinib is a selec­tive Janus kinase (JAK1 and JAK2) inhibitor, pri­mar­i­ly used to treat myelofi­bro­sis and poly­cythemia vera.
Rux­oli­tinib can inhib­it the pro­lif­er­a­tion and sur­vival of tumor cells, there­by slow­ing the growth of tumors. Addi­tion­al­ly, by inhibit­ing the JAK-STAT path­way, it can reduce inflam­ma­tion caused by tumors, alle­vi­at­ing symp­toms. The cyclopentyl struc­ture in 3-Cyclopen­ty­lacry­loni­trile is a cru­cial part of the Rux­oli­tinib mol­e­cule, essen­tial for the drug’s activ­i­ty and sta­bil­i­ty. This unique struc­ture helps Rux­oli­tinib achieve high selec­tiv­i­ty and effi­ca­cy in tar­get­ing JAK1 and JAK2 kinas­es, enhanc­ing its ther­a­peu­tic effect.

Gen­er­al View of Documents

This prod­uct is devel­oped by our R&D com­pa­ny Cam­ing Phar­ma­ceu­ti­cal Lim­it­ed (http://​www​.cam​ing​.com/).

Quick Inquiry

Fill out our inquiry form and one of our experts will be in touch with you shortly.

























    Please prove you are human by select­ing the plane.